Currently, hypoxia has presented association with immunotherapy response or immune checkpoint effects in many cancers (26–28), whereas only a clinical trial consisting of mixed melanoma patients suggested that the PD-1 blockage responders of immunotherapy has a reduced hypoxia transcriptomic change (29). Here, PDCD1 is linked to melanoma.